Novo Nordisk and MIT in Research Collaboration
September 07 2015 - 9:09AM
Dow Jones News
By Dominic Chopping
Danish insulin maker Novo Nordisk A/S (NVO) Monday announced a
collaboration with the Langer Laboratory at the Massachusetts
Institute of Technology to research the next generation of drug
delivery devices.
Research will be conducted at both MIT in Boston, U.S. and at
Novo Nordisk's research facilities in Malov and Hillerod, Denmark,
as they look to develop alternatives to traditional injection-based
methods.
"There are many challenges of developing and producing a
reliable peptide delivery vehicle," Novo Nordisk said in a
statement. "If these challenges can be overcome, as recent research
suggests, drug delivery devices hold great therapeutic promise for
a plethora of diseases where patients need to take frequent
injections."
The collaboration will establish a number of research positions
to be hosted by the Langer Laboratory and funded by Novo Nordisk.
The initial term of the collaboration is three years with the
option to extend for up to three additional years.
-Write to Dominic Chopping at dominic.chopping@wsj.com; Twitter:
@WSJNordics
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
September 07, 2015 08:54 ET (12:54 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Sep 2023 to Sep 2024
